Immunogenicity and Reactogenicity of an Inactivated SARS-CoV-2 Vaccine (BBV152) in Children Aged 2–18 Years: Interim Data from an Open-Label, Non-randomised, Age De-escalation Phase 2/3 Study
Scientists conducted an age de-escalation study to assess the safety, reactogenicity, and immunogenicity of an inactivated COVID-19 vaccine, BBV152, in children aged 2-18 years.
[Oncology Reports] The expression profiles of circRNAs and mRNAs were compared between gastric cancer‑MSCs and bone marrow‑derived MSCs using microarray analysis.
[Journal Of Clinical Pathology] Scientists evaluated the association between perilipin 1 or adipophilin expression and prognosis in liposarcoma. 97 primary resection specimens were examined.